AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates

Company Performance - AbCellera Biologics Inc. reported a quarterly loss of $0.19 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.17, marking an earnings surprise of -11.76% [1] - The company posted revenues of $8.96 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 35.31%, compared to revenues of $6.51 million in the same quarter last year [2] - Over the last four quarters, AbCellera has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - AbCellera shares have increased approximately 60.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 15.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.16 on revenues of $7.65 million, and for the current fiscal year, it is -$0.61 on revenues of $34.96 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which AbCellera belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]